CMO rises from biotech's ashes

Introgen Therapeutics, which filed for bankruptcy protection late last year, is getting a second shot at life, of sorts.

Houston investors have purchased the company's manufacturing-related assets, reports the Houston Business Journal, and from them formed contract manufacturer Vivante GMP Solutions. At bankruptcy, the Introgen assets were divided into three: manufacturing patents, therapeutic drug assets, and manufacturing-related assets. The investors took advantage of the latter, which include a facility and documentation required to manufacture third-party biologic drugs and clinical trials.

Vivante's focus is biologics for academic institutions and biotech companies. According to the press report, several biotechs have engaged the CMO, and it retained customers throughout the bankruptcy, as an Introgen subsidiary.

- see the article

Suggested Articles

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Continuing its expansion efforts, Japan’s Fujifilm will make a major investment in its U.S. gene therapy operation in Texas.